Global Pruritus Pipeline Review: H2 2019 -

DUBLIN--()--The "Pruritus - Pipeline Review, H2 2019" drug pipelines has been added to's offering.

This report provides an overview of the Pruritus (Dermatology) pipeline landscape.

The review provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 6, 1, 14, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Albireo Pharma Inc
  • Amgen Inc
  • AntalGenics SL
  • AOBiome LLC
  • Asana BioSciences LLC
  • Biomimetix JV LLC
  • Cara Therapeutics Inc
  • Celgene Corp
  • Chugai Pharmaceutical Co Ltd
  • DermaXon LLC
  • ELORAC Inc
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kiniksa Pharmaceuticals Corp
  • Kolmar Korea Holdings Co Ltd
  • Lumosa Therapeutics Co Ltd
  • MC2 Therapeutics AS
  • Menlo Therapeutics Inc
  • Neurim Pharmaceuticals Ltd
  • NeuroCycle Therapeutics GmbH
  • Patagonia Pharmaceuticals LLC
  • Peptide Logic LLC
  • RDD Pharma Ltd
  • Roivant Sciences Ltd
  • Saniona AB
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Shaperon Inc
  • Sienna Biopharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunny Pharmtech Inc
  • Teikoku Pharma USA Inc
  • Tioga Pharmaceuticals Inc
  • Toray Industries Inc
  • Trevi Therapeutics Inc
  • Vanda Pharmaceuticals Inc
  • Vivozon Inc

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900